Ralliant Corporation $RAL Shares Bought by SG Americas Securities LLC

SG Americas Securities LLC raised its stake in Ralliant Corporation (NYSE:RAL) by 546.3% in the 1st quarter, according to its most recent filing with the SEC. The fund owned 468,704 shares of the company’s stock after purchasing an additional 396,178 shares during the period. SG Americas Securities LLC owned 0.42% of Ralliant worth $19,493,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of RAL. Danske Bank A S acquired a new stake in Ralliant during the fourth quarter valued at approximately $25,000. Palisade Asset Management LLC acquired a new position in shares of Ralliant in the 3rd quarter worth approximately $26,000. V Square Quantitative Management LLC acquired a new position in shares of Ralliant in the 4th quarter worth approximately $26,000. Allworth Financial LP increased its holdings in shares of Ralliant by 134.4% in the 4th quarter. Allworth Financial LP now owns 511 shares of the company’s stock valued at $26,000 after acquiring an additional 293 shares during the last quarter. Finally, BOKF NA bought a new stake in shares of Ralliant in the 3rd quarter valued at approximately $29,000.

Ralliant Price Performance

Shares of NYSE RAL opened at $73.58 on Friday. Ralliant Corporation has a 1-year low of $37.27 and a 1-year high of $75.41. The company has a debt-to-equity ratio of 0.73, a current ratio of 1.61 and a quick ratio of 1.05. The business’s fifty day moving average price is $57.60 and its two-hundred day moving average price is $51.10. The firm has a market capitalization of $8.24 billion and a PE ratio of -6.73.

Ralliant (NYSE:RAL) last announced its quarterly earnings results on Tuesday, May 12th. The company reported $0.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.49 by $0.08. The company had revenue of $534.60 million during the quarter. Ralliant had a negative net margin of 58.55% and a positive return on equity of 12.49%. Ralliant’s revenue for the quarter was up 11.0% compared to the same quarter last year. Ralliant has set its FY 2026 guidance at 2.530-2.690 EPS and its Q2 2026 guidance at 0.580-0.640 EPS. On average, research analysts expect that Ralliant Corporation will post 2.64 EPS for the current year.

Ralliant Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, June 23rd. Shareholders of record on Monday, June 8th were paid a dividend of $0.05 per share. This represents a $0.20 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date of this dividend was Monday, June 8th. Ralliant’s payout ratio is presently -1.83%.

Analysts Set New Price Targets

RAL has been the topic of several research analyst reports. Truist Financial restated a “buy” rating and set a $68.00 price objective (up from $53.00) on shares of Ralliant in a research note on Wednesday, May 13th. Weiss Ratings reiterated a “sell (d)” rating on shares of Ralliant in a research note on Monday, May 4th. Vertical Research downgraded shares of Ralliant from a “buy” rating to a “hold” rating and set a $65.00 price target on the stock. in a research report on Wednesday, May 27th. Wall Street Zen raised shares of Ralliant from a “hold” rating to a “buy” rating in a report on Saturday, June 20th. Finally, Citigroup boosted their price objective on shares of Ralliant from $51.00 to $70.00 and gave the company a “buy” rating in a research report on Wednesday, May 13th. Seven research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $69.00.

Ralliant Profile

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.